Table 1.
Group | Overall N = 8,710 | Adalimumab n = 4,298 | Etanercept n = 2,795 | Infliximab n = 161 | Ustekinumab n = 1,465 |
---|---|---|---|---|---|
Patients, n (%) | 8,710 (100.0) | 4,289 (49.2) | 2,795 (32.1) | 161 (1.8) | 1,465 (16.8) |
Nonswitchers | 5,000 (57.4) | 2,436 (56.8) | 1,458 (52.2) | 100 (62.1) | 1,006 (68.7) |
Switchers | 1,001 (11.5) | 543 (12.7) | 359 (12.8) | 25 (15.5) | 74 (5.1) |
Discontinuers | 2,709 (31.1) | 1,310 (30.5) | 978 (35.0) | 36 (22.4) | 385 (26.3) |
aPercentages for treatment pattern subgroups were calculated from the total number of patients who initiated each therapy.